Literature DB >> 30044357

Management of Paediatric Ulcerative Colitis, Part 1: Ambulatory Care-An Evidence-based Guideline From European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition.

Dan Turner1, Frank M Ruemmele2, Esther Orlanski-Meyer1, Anne M Griffiths3, Javier Martin de Carpi4, Jiri Bronsky5, Gabor Veres6, Marina Aloi7, Caterina Strisciuglio8, Christian P Braegger9, Amit Assa10, Claudio Romano11, Séamus Hussey12, Michael Stanton13, Mikko Pakarinen14, Lissy de Ridder15, Konstantinos Katsanos16, Nick Croft17, Victor Navas-López18, David C Wilson19, Sally Lawrence20, Richard K Russell21.   

Abstract

BACKGROUND: The contemporary management of ambulatory ulcerative colitis (UC) continues to be challenging with ∼20% of children needing a colectomy within childhood years. We thus aimed to standardize daily treatment of pediatric UC and inflammatory bowel diseases (IBD)-unclassified through detailed recommendations and practice points.
METHODS: These guidelines are a joint effort of the European Crohn's and Colitis Organization (ECCO) and the Paediatric IBD Porto group of European Society of Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN). An extensive literature search with subsequent evidence appraisal using robust methodology was performed before 2 face-to-face meetings. All 40 included recommendations and 86 practice points were endorsed by 43 experts in Paediatric IBD with at least an 88% consensus rate.
RESULTS: These guidelines discuss how to optimize the use of mesalamine (including topical), systemic and locally active steroids, thiopurines and, for more severe disease, biologics. The use of other emerging therapies and the role of surgery are also covered. Algorithms are provided to aid therapeutic decision-making based on clinical assessment and the Paediatric UC Activity Index (PUCAI). Advice on contemporary therapeutic targets incorporating the use of calprotectin and the role of therapeutic drug monitoring are presented, as well as other management considerations around pouchitis, extraintestinal manifestations, nutrition, growth, psychology, and transition. A brief section on disease classification using the PIBD-classes criteria and IBD-unclassified is also part of these guidelines.
CONCLUSIONS: These guidelines provide a guide to clinicians managing children with UC and IBD-unclassified management to provide modern management strategies while maintaining vigilance around appropriate outcomes and safety issues.

Entities:  

Mesh:

Year:  2018        PMID: 30044357     DOI: 10.1097/MPG.0000000000002035

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN: 0277-2116            Impact factor:   3.288


  60 in total

1.  Positioning Biologic Therapies in the Management of Pediatric Inflammatory Bowel Disease.

Authors:  Jessica Breton; Arthur Kastl; Maire A Conrad; Robert N Baldassano
Journal:  Gastroenterol Hepatol (N Y)       Date:  2020-08

2.  Clinical and biological predictors of response to standardised paediatric colitis therapy (PROTECT): a multicentre inception cohort study.

Authors:  Jeffrey S Hyams; Sonia Davis Thomas; Nathan Gotman; Yael Haberman; Rebekah Karns; Melanie Schirmer; Angela Mo; David R Mack; Brendan Boyle; Anne M Griffiths; Neal S LeLeiko; Cary G Sauer; David J Keljo; James Markowitz; Susan S Baker; Joel Rosh; Robert N Baldassano; Ashish Patel; Marian Pfefferkorn; Anthony Otley; Melvin Heyman; Joshua Noe; Maria Oliva-Hemker; Paul A Rufo; Jennifer Strople; David Ziring; Stephen L Guthery; Boris Sudel; Keith Benkov; Prateek Wali; Dedrick Moulton; Jonathan Evans; Michael D Kappelman; M Alison Marquis; Francisco A Sylvester; Margaret H Collins; Suresh Venkateswaran; Marla Dubinsky; Vin Tangpricha; Krista L Spada; Bradley Saul; Jessie Wang; Jose Serrano; Kevin Hommel; Urko M Marigorta; Greg Gibson; Ramnik J Xavier; Subra Kugathasan; Thomas Walters; Lee A Denson
Journal:  Lancet       Date:  2019-03-29       Impact factor: 79.321

3.  Probiotics for maintenance of remission in ulcerative colitis.

Authors:  Zipporah Iheozor-Ejiofor; Lakhbir Kaur; Morris Gordon; Patricia Anne Baines; Vasiliki Sinopoulou; Anthony K Akobeng
Journal:  Cochrane Database Syst Rev       Date:  2020-03-04

4.  Probiotics for induction of remission in ulcerative colitis.

Authors:  Lakhbir Kaur; Morris Gordon; Patricia Anne Baines; Zipporah Iheozor-Ejiofor; Vasiliki Sinopoulou; Anthony K Akobeng
Journal:  Cochrane Database Syst Rev       Date:  2020-03-04

5.  Efficacy and safety of infliximab in very early onset inflammatory bowel disease: a national comparative retrospective study.

Authors:  Matteo Bramuzzo; Serena Arrigo; Claudio Romano; Maria Chiara Filardi; Paolo Lionetti; Anna Agrusti; Valeria Dipasquale; Monica Paci; Giovanna Zuin; Marina Aloi; Caterina Strisciuglio; Erasmo Miele; Maria Pastore; Stefano Martelossi; Patrizia Alvisi
Journal:  United European Gastroenterol J       Date:  2019-04-25       Impact factor: 4.623

Review 6.  Therapeutic Advances in Gut Microbiome Modulation in Patients with Inflammatory Bowel Disease from Pediatrics to Adulthood.

Authors:  Adi Eindor-Abarbanel; Genelle R Healey; Kevan Jacobson
Journal:  Int J Mol Sci       Date:  2021-11-19       Impact factor: 5.923

Review 7.  Ulcerative Colitis-Diagnostic and Therapeutic Algorithms.

Authors:  Torsten Kucharzik; Sibylle Koletzko; Klaus Kannengiesser; Axel Dignass
Journal:  Dtsch Arztebl Int       Date:  2020-08-17       Impact factor: 5.594

8.  Normal fecal calprotectin levels in healthy children are higher than in adults and decrease with age.

Authors:  Marta Velasco Rodríguez-Belvís; Javier Francisco Viada Bris; Carmen Plata Fernández; Alberto García-Salido; Julia Asensio Antón; Gloria Domínguez Ortega; Rosa Ana Muñoz Codoceo
Journal:  Paediatr Child Health       Date:  2019-06-17       Impact factor: 2.253

9.  Immunogenicity of cholera vaccination in children with inflammatory bowel disease.

Authors:  Łukasz Dembiński; Anna Stelmaszczyk-Emmel; Katarzyna Sznurkowska; Agnieszka Szlagatys-Sidorkiewicz; Andrzej Radzikowski; Aleksandra Banaszkiewicz
Journal:  Hum Vaccin Immunother       Date:  2021-04-01       Impact factor: 3.452

10.  Usefulness of Measuring Thiopurine Metabolites in Children with Inflammatory Bowel Disease and Autoimmunological Hepatitis, Treated with Azathioprine.

Authors:  Katarzyna Bąk-Drabik; Piotr Adamczyk; Justyna Duda-Wrońska; Dominika Dąbrowska-Piechota; Anna Jarzumbek; Jarosław Kwiecień
Journal:  Gastroenterol Res Pract       Date:  2021-06-17       Impact factor: 2.260

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.